

# FEE TRANSMITTAL

Complete If Known

Application No. 10/091,007  
Filing Date March 6, 2002  
First Named Inventor Le PAGE, et al.  
Examiner Name S. Devi  
Group Art Unit 1645

Total Amount Of Payment (\$)

Attorney Docket No. 62785.000002

## METHOD OF PAYMENT (check one)

1. ☒ The Commissioner for Patents is hereby authorized to charge indicated fees and credit any over payments to **Deposit Account No. 50-0206** in the name of Hunton & Williams LLP.

2. ☒ Check Enclosed. The Commissioner for Patents is hereby authorized to charge any variance between the amount enclosed and the Patent Office charges to **Deposit Account No. 50-0206** in the name of Hunton & Williams LLP, 1900 K Street, N.W., Suite 1200, Washington, D.C. 20006-1109.

## FEE CALCULATION

BASIC FILING FEE ☒ Large Entity ☐ Small Entity

UTILITY FILING FEE \$  
DESIGN FILING FEE \$  
PLANT FILING FEE \$  
REISSUE FILING FEE \$  
PROVISIONAL FILING FEE \$

## FEE PAID

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Fee Description	Fee Paid
<input type="checkbox"/> Surcharge - late filing fee or oath	\$
<input type="checkbox"/> Surcharge - late provisional filing fee or cover sheet	\$
<input type="checkbox"/> _____ Month Extension of Time	\$
<input type="checkbox"/> Notice of Appeal	\$
<input type="checkbox"/> Filing Brief in Support of Appeal	\$
<input type="checkbox"/> Request for Oral Hearing	\$
<input type="checkbox"/> Utility Issue Fee (or Reissue) (including Publication Fee, if necessary)	\$
<input type="checkbox"/> Design Issue Fee	\$
<input type="checkbox"/> Plant Issue Fee	\$
<input type="checkbox"/> Petition to Commissioner	\$
<input type="checkbox"/> Petition to Revive (Unavoidable)	\$
<input type="checkbox"/> Petition to Revive (Unintentional)	\$
<input type="checkbox"/> Petitions Related to Provisional Applications	\$
<input type="checkbox"/> Submission of Information Disclosure Statement	\$
<input type="checkbox"/> Filing Submission After Final Rejection	\$
<input type="checkbox"/> Recording Each Patent Assignment Per Property	\$
<input type="checkbox"/> Filing Request for Reexamination	\$
<input type="checkbox"/> Other (specify) _____	\$

## 2. EXTRA CLAIMS FEES

### CLAIMS AS AMENDED


For	Number Present	Highest Number Paid For	Extra	Rate		Amount
				Large Entity	Small Entity	
TOTAL CLAIMS				x \$ 18.00	x \$ 9.00	\$
INDEPENDENT CLAIMS				x \$ 86.00	x \$ 43.00	\$
MULTIPLE DEPENDENT CLAIMS				\$ 290.00	\$ 145.00	\$
TOTAL EXTRA CLAIMS FEES						\$

### SUBMITTED BY

Complete (if applicable)

Typed or Printed Name David Kelly  
Signature *David Kelly*  
Date February 2, 2004  
Registration No. 53,106

The PTO did not receive the following listed item(s) the check



1645

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of :

LE PAGE, *et al.*

Serial No.: 10/091,007

Filed: March 6, 2002

Examiner: Devi, S.

Group Art Unit: 1645

For: NUCLEIC ACIDS AND PROTEINS FROM GROUP B STREPTOCOCCUS

**Preliminary Amendment Under 37 C.F.R. § 1.115 and Response to Notice to Comply with  
Requirements for Patent Applications Containing Nucleotide Sequence and/or  
Amino Acid Sequence Disclosures**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the attached U.S. Patent and Trademark Office (PTO) Notice to Comply with requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed December 2, 2003, and in accordance with the provisions of 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith a "Sequence Listing" in both paper copy and computer readable form.

Applicants submit herewith a computer readable copy of the substitute "Sequence Listing" on a CD-ROM in ASCII format as required by 37 C.F.R. § 1.821(e). In accordance with the provisions of 37 C.F.R. § 1.821(f), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the "Sequence Listing" submitted herewith are the same.

Applicants additionally request that the specification be amended as submitted below to conform with the Sequence Listing request. No new matter is introduced as a result of these amendments.

Please amend the above captioned application as set forth below.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Drawings** begin on page 8 of this paper and include both an attached replacement sheet and an annotated sheet showing changes.

**Remarks/Arguments** begin on page 9 of this paper.

An **Appendix** including amended drawing figures is attached following page 9 of this paper.